Bristol-myers Squibb Compnay

Novartis Ag

Douglas Michael Robinson

Ricardo Attar

Marco Gottardis

Joan Carboni

Yaping Shou

Fei Huang

Xia Han

Ashok Ramesh Dongre

Raj Bandaru

Jiwen Chen

Gayle M Wittenberg

Warren Hurlburt

Rameh Hafezi

Asifa Haider

Thad Tyson Sharp

Kristine Lynn Rose

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Growing community of inventors

Hanover, MA, United States of America

Douglas Michael Robinson